Jiangsu Bioperfectus Technologies Co

Jiangsu Bioperfectus Technologies Co EBITDA per Employee

The EBITDA per Employee of Jiangsu Bioperfectus Technologies Co (688399.SS) as of Oct 28, 2026 is -29,219.78 CNY. In the previous year, EBITDA per Employee was 39,912.41 CNY — a change of -173.21% (lower).

EBITDA per Employee

-29,219.78CNY

YoY

-173.21%

Last updated:

EBITDA per Employee of Jiangsu Bioperfectus Technologies Co is 2025 -29,219.78 CNY. EBITDA per Employee of Jiangsu Bioperfectus Technologies Co was 2024 39,912.41 CNY. It decreases by -173.21% lower compared to the previous year.

The Jiangsu Bioperfectus Technologies Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
79,473.88 CNY
Jan 1, 2019
102,533.66 CNY
Jan 1, 2020
908,324.31 CNY
Jan 1, 2021
1.32 M CNY
Jan 1, 2022
2.04 M CNY
Jan 1, 2023
-288,422.87 CNY
Jan 1, 2024
39,912.41 CNY
Jan 1, 2025
-29,219.78 CNY
The Jiangsu Bioperfectus Technologies Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-29,219.78CNY-173.21%
39,912.41CNY-113.84%
-288,422.87CNY-114.12%
2.04 MCNY+54.98%
1.32 MCNY+45.07%
908,324.31CNY+785.88%
102,533.66CNY+29.02%
79,473.88CNY+44.38%
55,046.32CNY+339.24%
12,532.20CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jiangsu Bioperfectus Technologies Co Stock analysis

What does Jiangsu Bioperfectus Technologies Co do? Jiangsu Bioperfectus Technologies Co., Ltd. generates revenue through the research, development, production, and sale of in vitro diagnostic reagents and supporting testing instruments. The company's primary products include in vitro diagnostic reagents, supporting testing instruments, and in vitro testing services, which are utilized in infectious disease prevention and control, clinical testing, large-scale population screening, and prenatal and postnatal care management. Domestic and overseas markets represent the main sales channels for these products, with the firm targeting healthcare providers and laboratories that require diagnostic solutions for disease detection and patient care. The company's focus on in vitro diagnostic reagents and supporting instruments positions it within the healthcare sector, serving customers who need reliable testing tools for clinical and public health applications. By offering comprehensive diagnostic solutions, Jiangsu Bioperfectus addresses the needs of medical institutions and public health initiatives, particularly in areas such as infectious disease management and maternal care. The firm's product portfolio supports both routine clinical testing and specialized population screening programs. Jiangsu Bioperfectus Technologies Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jiangsu Bioperfectus Technologies Co stock

EBITDA per Employee of Jiangsu Bioperfectus Technologies Co is -29,219.78 CNY in 2025.

EBITDA per Employee of Jiangsu Bioperfectus Technologies Co changed from 39,912.41 CNY to -29,219.78 CNY, representing a -173.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Jiangsu Bioperfectus Technologies Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Jiangsu Bioperfectus Technologies Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Jiangsu Bioperfectus Technologies Co

All Key Metrics — Jiangsu Bioperfectus Technologies Co